title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Participants | RECRUITMENT | The following participant groups were recruited for involvement in both the question submission and the Delphi prioritisation:Clinicians involved in neonatal care: neonatologists, paediatricians, trainee doctors, neonatal nurses and advanced neonatal nurse practitioners were contacted through professional organisations... | PMC10646876 | |
Question design and submission | ’ | A bespoke platform for question submission was devised using ‘OnlineSurvey’ (Jisc Services Limited, UK) software, with iterative development and face validity testing from all steering group members. The platform guided participants through the practicalities of structuring questions in the PICO format. We used categor... | PMC10646876 | |
Prioritisation process | All eligible research questions were entered into a three-round eDelphi survey using ‘DelphiManager’ (Comet Initiative Delphi Manager, University of Liverpool, UK) software, to establish a consensus as to their importance. Participants were asked to rank each research question on a 9-point Likert scale with 1 represent... | PMC10646876 | ||
Parental and former patient involvement | To maximise accessibility for non-clinical participants, guidance was provided by the study steering group parent representative throughout the prioritisation process. Advice was sought from key advocacy organisations such as Bliss to determine how best to meaningfully involve parents and ex-neonatal patients while kee... | PMC10646876 | ||
Results | The national neonatal priority setting partnership was completed as outlined in the study protocol. | PMC10646876 | ||
Question development | ’ | Two hundred and sixty-five questions were submitted in PICO format during the 1-month submission period, from a total of 108 participants. The most common themes for questions were feeding and nutrition (20%) and family integrated care (20%). Stakeholder group breakdown was 11% parents, 4% nurses, 49% doctors, 11% AHPs... | PMC10646876 | |
eDelphi survey | MAY | The three-phase online Delphi survey opened in May and was completed in August 2022; over 200 participants registered their interest. One hundred and sixty-four questions were eligible for entry into the first round of the survey which was completed by 144 participants. Raw scores displayed a bimodal distribution when ... | PMC10646876 | |
Final list of prioritised research questions | All eligible questions were amalgamated into a final list of prioritised research questions and can be viewed in
Final list of top 10 prioritised research questions | PMC10646876 | ||
Discussion | Using a robust, reproducible consensus methodology, we have identified and prioritised 186 neonatal research questions suitable for definitive interventional clinical trials. Through involvement of a broad range of stakeholders, the results are generalisable to the wider neonatal community in the UK. These results shou... | PMC10646876 | ||
Data availability statement | All data relevant to the study are included in the article or uploaded as supplemental information. All data relevant to this study are uploaded as supplemental information. | PMC10646876 | ||
Ethics statements | PMC10646876 | |||
Patient consent for publication | Not required. | PMC10646876 | ||
Ethics approval | Research Ethics Committee approval was not required as the study did not recruit participants. | PMC10646876 | ||
References | PMC10646876 | |||
Abstract | PMC10757135 | |||
Background | mCRC, toxicities, HFSR, hand‐foot skin reaction | METASTATIC COLORECTAL CANCER, HYPERTENSION | Fruquintinib has demonstrated significant improvement in overall survival (OS) among previously treated metastatic colorectal cancer (mCRC) patients. However, the utilization of fruquintinib has been constrained by various toxicities, such as hand‐foot skin reaction (HFSR) and hypertension, particularly in elderly pati... | PMC10757135 |
Patients and Methods | toxicity | This open‐label, single‐arm, phase II trial included patients aged 65 years or over with mCRC who had progressed after two or more lines of chemotherapy. Fruquintinib was administered for 21 consecutive days of a 28‐day treatment cycle. The starting dose of fruquintinib was 3 mg/day and escalated to 4 mg/day in Week 2 ... | PMC10757135 | |
Results | hypertension, HFSR, diarrhea | ADVERSE EVENTS, HYPERTENSION | A total of 29 patients were enrolled and all started fruquintinib at 3 mg/day. Fifteen patients (51.7%) were subsequently escalated to 4 mg/day and 4 (13.8%) to 5 mg/day. Only four (13.8%) patients discontinued treatment due to adverse events (AEs). The median PFS was 3.8 months (95% CI, 2.7–4.9), and the median OS was... | PMC10757135 |
Conclusion | Our study indicated that a dose of 4 mg/day was well tolerated by most elderly patients, suggesting that fruquintinib dose‐escalation strategy during the first cycle could serve as a viable alternative to the standard 5 mg/day dosing.
Sirui Tan and Shunyu Zhang contributed equally to this work. | PMC10757135 | ||
INTRODUCTION | colorectal cancer, tumor, CRC, toxicity, cancer, various malignant tumors | COLORECTAL CANCER, TUMOR, ONCOGENESIS, CANCER, TUMOR ANGIOGENESIS, ONCOLOGY | Globally, colorectal cancer (CRC) ranks third in incidence and second in tumor‐related mortality among various malignant tumors in the world.Fruquintinib is a potent and highly selective small‐molecule inhibitor of vascular endothelial growth factor receptor (VEGFR)‐1, ‐2, and ‐3 that inhibit tumor angiogenesis.In clin... | PMC10757135 |
METHODS | PMC10757135 | |||
Patients and study design | Tumors, active hepatitis, arrhythmia, Cancer | UNCONTROLLED HYPERTENSION, METASTASIS, ARRHYTHMIA, TUMORS, WEST, ONCOLOGY, HEART FAILURE, CORONARY ARTERY DISEASE, CANCER | This phase II prospective, single‐arm, open‐label, multicenter study was conducted at West China Hospital of Sichuan University, West China Fourth Affiliated Hospital of Sichuan University, Sichuan Cancer Hospital, and Sichuan Provincial People's Hospital. The study strictly adhered to the Helsinki provisions of the De... | PMC10757135 |
Procedures | bleeding, hand‐foot skin reaction, toxicity, abnormal liver function, proteinuria, Depression, Cancer | ADVERSE EVENT, BLEEDING, DISEASE PROGRESSION, ADVERSE EVENTS, HYPERTENSION, CANCER | All included patients underwent GA and G8 screening tool before treatment. GA included Instrumental (IADL) and Activities in Daily Living (ADL) questionnaires, the Mini‐Nutritional Assessment (MNA), the Geriatric Depression Scale‐15 (GDS‐15), the Mini‐Mental State Examination (MMSE), the Cumulative Illness Rating Scale... | PMC10757135 |
Outcomes | death, Tumor, cancer, SD, PD | DISEASE PROGRESSION, DISEASE, CANCER, TUMOR | The primary endpoint was progression‐free survival (PFS) defined as the time from the start of treatment to the first verifiable disease progression or death due to cancer. Secondary endpoints were overall survival (OS), safety, and objective response rate (ORR). OS is defined as the time from the start of treatment to... | PMC10757135 |
Statistical analysis | In the phase II REGOLD study, the median PFS was 2.2 months. With a PFS threshold of 2.2 months and an expected PFS of 4.0 months, simulation results indicated a sample size of 26 with Patient baseline characteristics were described. PFS and OS were estimated using Kaplan–Meier survival curves. The correlation between ... | PMC10757135 | ||
RESULTS | PMC10757135 | |||
Patient characteristics | hypertension | PRIMARY TUMOR, LIVER METASTASES, HYPERTENSION, TYPE 2 DIABETES | Between November 6, 2020, and January 19, 2022, a total of 29 patients were enrolled in the study, and the cutoff date for OS was October 30, 2022. The median age of the patients was 69 years (range: 65–77), and 16 (44.8%) were male. Only 13.8% (4/29) of patients had an ECOG of 0. The primary tumor was located in the r... | PMC10757135 |
Treatment exposure and efficacy | Among 29 patients, 34.5% (10/29) patients had a maximum tolerated dose of 3 mg fruquintinib, 51.7% (15/29) patients had a maximum tolerated dose of 4 mg, and only 13.8% (4/29) patients could tolerate a therapeutic dose of 5 mg. The weekly dosing history for patients up to Week 1 of Cycle 3 is summarized in Figure Swimm... | PMC10757135 | ||
Safety | diarrhea, fatigue, decreased appetite, hypertension, hand‐foot syndrome | ADVERSE EVENTS, HYPERTENSION | Treatment‐related adverse events (TRAEs) were observed in all 29 patients (100%). Common AEs (>40%) included fatigue (23/29; 79.3%), decreased appetite (17/29; 58.6%), and hand‐foot syndrome (13/29; 44.8%). The most frequently occurring (>10%) TRAEs greater than Grade 3 were hand‐foot syndrome (6/29; 20.7%), hypertensi... | PMC10757135 |
DISCUSSION | hypertension, colon cancer, fatigue | DISEASE PROGRESSION, HYPERTENSION, COLON CANCER | This study is the first to evaluate the efficacy and safety of fruquintinib initial dose‐escalation strategy for elderly patients with refractory mCRC. The mPFS in patients who were treated with this strategy was 3.8 months, and the primary reason for discontinuation of treatment was disease progression. The majority o... | PMC10757135 |
CONCLUSIONS | Our study indicated that fruquintinib weekly dose‐escalation strategy during the first cycle maintained its efficacy and its safety profile was tolerable. Physicians may consider this fruquintinib dose‐escalation strategy as a viable alternative to the standard 5 mg/day dosing in the management of elderly patients with... | PMC10757135 | ||
AUTHOR CONTRIBUTIONS | PMC10757135 | |||
FUNDING INFORMATION | None. | PMC10757135 | ||
CONFLICT OF INTEREST STATEMENT | The authors have no conflict of interest. | PMC10757135 | ||
ACKNOWLEDGMENTS | Cancer | WEST, CANCER | We express our gratitude to West China Hospital of Sichuan University, West China Fourth Affiliated Hospital of Sichuan University, Sichuan Cancer Hospital, and Sichuan Provincial People's Hospital for their understanding of our research and the provision of data. | PMC10757135 |
DATA AVAILABILITY STATEMENT | The data that support the findings of this study are available from the corresponding author upon reasonable request. | PMC10757135 | ||
REFERENCES | PMC10757135 | |||
Background | PsA, tumor necrosis | PSORIATIC ARTHRITIS, TUMOR NECROSIS | Guselkumab is a selective interleukin (IL)-23 inhibitor targeting the IL-23p19 subunit. In the phase 3b COSMOS trial, guselkumab demonstrated efficacy in treating participants with active psoriatic arthritis (PsA) and inadequate response (IR; lack of efficacy or intolerance) to tumor necrosis factor inhibitors (TNFi). | PMC10428525 |
Methods | PsA, swollen joints, tumor necrosis, psoriasis | DISEASE, TUMOR NECROSIS, PSORIASIS | Adults with active PsA (≥ 3 swollen joints, ≥ 3 tender joints) and IR to one or two TNFi (TNFi-IR) were randomized 2:1 to guselkumab at Weeks 0, 4, then every 8 weeks (Q8W) or placebo➔guselkumab Q8W at Week 24 with possible early escape at Week 16. Levels of serum cytokines, including interferon γ (IFNγ), IL-10, and t... | PMC10428525 |
Results | psoriasis | PSORIASIS | Baseline serum levels of IL-6, IL-10, IL-17A, IL-17F, IL-22, TNFα, and IFNγ were significantly higher in COSMOS TNFi-IR participants than in healthy controls. Baseline IL-6, CRP, and SAA levels were associated with baseline DAS28-CRP. IL-17A and IL-17F levels were associated with baseline PASI score and psoriasis BSA. ... | PMC10428525 |
Conclusions | PsA, skin disease, arthritis | SKIN DISEASE, ARTHRITIS | Results from COSMOS participants with active, TNFi-IR PsA suggest guselkumab reduces levels of effector cytokines associated with the IL-23/IL-17 pathway, including those associated with baseline arthritis and skin disease activity. | PMC10428525 |
Trial registration | ClinicalTrials.gov: NCT03796858. | PMC10428525 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s13075-023-03125-4. | PMC10428525 | ||
Keywords | PMC10428525 | |||
Background | PsA, heterogenous, Psoriatic arthritis | PSORIATIC ARTHRITIS, INFLAMMATORY DISEASE | Psoriatic arthritis (PsA) is a heterogenous and chronic systemic inflammatory disease that can manifest in multiple domains [Guselkumab is a high-affinity, fully human, monoclonal antibody that targets the IL-23p19 subunit [Previous analyses have shown that C-reactive protein (CRP) and type 17 effector cytokine serum l... | PMC10428525 |
Methods | PMC10428525 | |||
Study design, participants, and endpoints | The study design and participant eligibility criteria for COSMOS have been previously described [ | PMC10428525 | ||
Clinical assessments | DISEASE, DISEASE | Among participants in the biomarker cohort, baseline disease activity was evaluated using SJC, TJC, 28-joint Disease Activity Score using CRP (DAS28-CRP) [ | PMC10428525 | |
Biomarker sample collection | PsA, psoriasis | SEPARATION, PSORIASIS, INFLAMMATION | In COSMOS, blood samples for biomarker analyses were collected from all participants at Weeks 0, 4, 16, 24, and 48 into standard serum separation tubes. After 30 min, serum was separated via centrifugation at room temperature (15–20 min at 1500 × Serum samples from 24 healthy control volunteers (defined as those with n... | PMC10428525 |
Biomarker analyses | tumor necrosis | INFLAMMATION, ADHESION, TUMOR NECROSIS | Serum samples for biomarker analyses were analyzed using qualified antibody-based assays. Serum concentrations of the T helper 17 (Th17) effector cytokine IL-17A were analyzed using Simoa™ single molecule array technology (Quanterix Corp., Billerica, MA), and those of IL-17F and IL-22 were analyzed using the Single Mol... | PMC10428525 |
Statistical analysis | This analysis included participants with available baseline values and follow-up biomarker and clinical data over time. All analyses were post hoc; thus, reported | PMC10428525 | ||
Analysis of treatment effect on clinical efficacy | Differences in efficacy outcomes evaluated in the COSMOS biomarker cohort with guselkumab versus placebo treatment were assessed using a Chi-square test (categorical outcomes) or ANOVA (continuous measures). | PMC10428525 | ||
Analysis of baseline serum biomarker levels and correlation with disease activity | PsA | REGRESSION, DISEASE | Differences in baseline serum cytokine levels between participants with PsA and healthy controls were assessed using log2-transformed data with a general linear model. Serum protein expression levels were log2-transformed to normalize the data distribution. Differences of ≥ 1.4-fold with Correlations between baseline ... | PMC10428525 |
Analysis of treatment effect on biomarker levels | For the evaluation of treatment effects (pharmacodynamic responses), changes in biomarker levels were compared between the active treatment and placebo groups. A contrast dataset for within-participant changes in biomarkers was generated from log2-transformed data, with the difference between the time point and baselin... | PMC10428525 | ||
Analysis of association between biomarker levels and clinical response | Differences in baseline biomarker levels by clinical response at Week 24 (i.e., response versus nonresponse for ACR20/50, IGA 0/1, and PASI75) were evaluated using general linear model analyses and log2-transformed biomarker levels. Clinical response categorical variable was set as the primary fixed factor. In determin... | PMC10428525 | ||
Results | PMC10428525 | |||
COSMOS participants and COSMOS biomarker cohort | PsA | DISEASE CHARACTERISTIC | In COSMOS, 189 participants with active TNFi-IR PsA were randomized to receive guselkumab Q8W, and 96 participants were randomized to receive placebo followed by guselkumab. Of these, 100 and 50 participants, respectively, were included in the biomarker cohort. In the COSMOS biomarker cohort, 21/100 (21%) participants ... | PMC10428525 |
Clinical efficacy in the COSMOS biomarker cohort | Among participants in the biomarker cohort, 44% in the guselkumab group versus 20% in the placebo group achieved an ACR20 response at Week 24 ( | PMC10428525 | ||
Biomarker analyses | PMC10428525 | |||
Baseline serum levels and correlation with baseline disease activity | PsA, tumor necrosis, Psoriasis, psoriasis, PsO | TUMOR NECROSIS, PSORIASIS, PSORIASIS, PSORIATIC ARTHRITIS, ADHESION, PSORIATIC ARTHRITIS, DISEASE | Baseline serum concentrations of IL-6, IL-10, IL-17A, IL-17F, IL-22, TNFα, and IFNγ were significantly higher in the COSMOS biomarker cohort compared with healthy controls (Fig. Baseline levels of serum cytokines (IL-10, TNFα, and IFNγ), Th17 effector cytokines (IL-17A, IL-17F, and IL-22) and acute phase proteins (CRP,... | PMC10428525 |
Effect of treatment on biomarker levels | PsA | In participants randomized to guselkumab, reductions from baseline in levels of the Th17 effector cytokines IL-17A, IL-17F, and IL-22 and the acute phase proteins IL-6, CRP, and SAA were observed, while changes from baseline were not apparent in those who received placebo (Fig. Serum levels of IL-17A, IL-17F, IL-22, CR... | PMC10428525 | |
Biomarker levels and clinical response | PsA | Participants in the guselkumab group, but not the placebo group, who achieved an ACR20 response at Week 24 exhibited higher baseline IL-22 and IFNγ levels compared with ACR20 nonresponders (Fig. Baseline serum cytokine levels and clinical response at Week 24 in participants with TNFi-IR PsA from COSMOS by ACR20 respons... | PMC10428525 | |
Discussion | PsA, skin disease, PsA disease, PsA. | DISORDER, SKIN DISEASE, DISEASE, JOINT DISEASE, PATHOGENESIS | These results provide further support for the important role of the IL-23/IL-17 pathway in PsA pathogenesis and expand our knowledge of guselkumab pharmacodynamic effects in patients with TNFi-IR PsA. Baseline levels of IL-6, IL-10, IL-17A, IL-17F, IL-22, TNFα, and IFNγ were higher in participants with TNFi-IR PsA comp... | PMC10428525 |
Conclusions | Overall, these data suggest that guselkumab reduces the levels of key effector inflammatory cytokines, including those associated with the IL-23/IL-17 pathway, at early time points in participants with TNFi-IR PsA. Reductions were generally sustained through Week 48, with levels of IL-17F, IL-22, CRP, and SAA approxima... | PMC10428525 | ||
Acknowledgements | Medical writing support was provided by Bret Fulton, RPh, and Jeanne McKeon, PhD, of Lumanity Communications Inc., under the direction of the authors in accordance with Good Publication Practice guidelines ( | PMC10428525 | ||
Authors’ contributions | GS | GS, SG, SDC, and MShawi contributed to the conception and/or design of the work and data interpretation. WC contributed to the conception and/or design of the work and data analysis and interpretation. FL, MZ, MSharaf, LCC, and SS contributed to data interpretation. All authors contributed to drafting and/or substantiv... | PMC10428525 | |
Funding | This study was sponsored by Janssen Research & Development, LLC, Spring House, PA, USA. | PMC10428525 | ||
Availability of data and materials | Johnson & Johnson is | The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at | PMC10428525 | |
Declarations | PMC10428525 | |||
Ethics approval and consent to participate | The governing ethical bodies for each of the 84 participating sites approved the COSMOS trial protocol. | PMC10428525 | ||
Consent for publication | Not applicable. | PMC10428525 | ||
Competing interests | Johnson & Johnson, of which Janssen, Johnson & Johnson., Johnson & Johnson MEA | GS has received speaker fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen, Novartis, and UCB.WC and SG are employees of Janssen Research & Development, LLC, and own stock or stock options in Johnson & Johnson, of which Janssen Research & Development, LLC is a wholly owned subsidiary.SDC is an em... | PMC10428525 | |
References | PMC10428525 | |||
Introduction | Cervical cancer | CERVICAL CANCER, SECONDARY, CERVICAL CANCER | Cervical cancer (CC) rates are high in Uganda, yet CC screening rates are very low. Our peer advocacy group intervention, Game Changers for Cervical Cancer Prevention (GC-CCP), was shown to increase CC screening uptake among social network members. In this secondary analysis, we examined mediators and moderators of thi... | PMC10173559 |
Methods | REGRESSION | We conducted a pilot randomized controlled trial of GC-CCP in Namayingo district, Eastern Uganda between September 2021 and April 2022. Forty adult women who had screened for CC in the past year (index participants) enrolled at baseline: 20 were randomized to receive the 7-session intervention to empower women to engag... | PMC10173559 | |
Results | pre-cancerous lesions | Increased alter engagement in CC prevention advocacy fully mediated the intervention effect on alter uptake of CC screening, and was associated with an increased likelihood of alter CC screening. CC treatment status of the index participant was the sole moderator of the intervention effect, as those in the intervention... | PMC10173559 | |
Conclusion | The effect of GC-CCP on alter CC screening is greater when the alter reports increased engagement in her own advocacy for CC prevention with others. The intervention effects on increased engagement in CC prevention advocacy among both index and alter participants suggest a diffusion of advocacy, which bodes well for di... | PMC10173559 | ||
Keywords | PMC10173559 | |||
Introduction | INVASIVE CANCER, PRECANCEROUS LESIONS, CERVICAL CANCER | The World Health Organization (WHO) estimates that implementation of cost-effective and evidence-based interventions, including human papillomavirus (HPV) vaccination of girls, screening and treatment of precancerous lesions, and improving access to diagnosis and treatment of invasive cancers will reduce the median cer... | PMC10173559 | |
Methods | PMC10173559 | |||
Study setting | cancer, Cancer | CANCER, CANCER | This analysis uses data collected as part of a randomized control trial of GC-CCP in Eastern Uganda between September 2021 and April 2022. The pilot study was conducted at Buyinja Health Center IV and Banda Health Center III in Namayingo, a rural community in the Busoga region of Uganda. The selection of the study site... | PMC10173559 |
Study design | The study design has been described in detail in our previous publication [ | PMC10173559 | ||
Participants | pre-cancerous or cancerous lesions | DISEASE, RECRUITMENT | Index participants were enrolled into the study if they were aged 18 years or older, had screened for CC within the past year, had stable health status (i.e., not in end stages of disease, so that they were likely to complete the 6-month study follow-up), and had shared their CC screening experience with at least one w... | PMC10173559 |
Intervention | The intervention has been described previously [The sessions were conducted using a structured facilitator manual, in the predominant local languages of Samia and Lusoga, by two peer facilitators from Namayingo who themselves had been screened for CC. The facilitators were trained by the senior investigators over three... | PMC10173559 | ||
Measures | Assessments included a standard survey (index and alter participants) and social network assessment (index participant only), which were administered in either Samia or Lusoga (depending on the preference of the participant) using Network Canvas computer-assisted software. Each measure was assessed with both index and ... | PMC10173559 | ||
CC screening and treatment | cancerous lesions, pre-cancerous lesions, pre-cancerous | Data were collected to determine if the participant had ever been screened for CC using visual inspection using acetic acid (VIA) or pap smear, and if so, when. For participants who had been screened, it was determined if the screening resulted in pre-cancerous lesions or potential cancerous lesions, in separate items;... | PMC10173559 | |
Potential mediators | The following measures were assessed as potential mediators of the effects of intervention effect on alter CC screening, as each was targeted by the components of the intervention. | PMC10173559 | ||
Potential moderators | SECONDARY | The variables we examined as potential moderators among both index and alter participants consisted of age and any secondary education, in addition to CC-related treatment history (index participants only) and presence of a main sex partner (alter participants only). | PMC10173559 | |
Data analysis | REGRESSION, SECONDARY | Descriptive and bivariate (2-tailed independent t-tests; chi-square or Fisher’s Exact tests) statistics were used to compare baseline sample characteristics of index and alter participants in the control versus intervention arms, in separate analyses. To examine intervention effects on index and alter measures of CC-re... | PMC10173559 | |
Ethical considerations | The study protocol was reviewed and approved by the Makerere University School of Public Health Research and Ethics Committee, and the Uganda National Council for Science and Technology. | PMC10173559 | ||
Results | PMC10173559 | |||
Sample characteristics | SECONDARY | Of the 40 index participants, 57.5% were older than 35 years, 22.5% had any secondary education, 87.5% reported that they had a main sexual partner, 92.5% had children, and 7.5% were HIV-positive. There were no significant differences between the index participants randomized to the intervention and those that were ran... | PMC10173559 | |
Mediation of the intervention effect on alter CC screening by index participant measures | SE | REGRESSION, CERVICAL CANCER, SECONDARY | Table
Bivariate and multivariate correlates of cervical cancer (CC) screening among alters* Bivariate analysis was conducted using 2-tailed independent t-tests. Multiple logistic regression models of alter uptake of CC screening included the month 6 measure of alter CC screening as the dependent variable, and the mont... | PMC10173559 |
Mediation of the intervention effect on alter CC screening by alter participant measures | SE | REGRESSION, CERVICAL CANCER, SECONDARY | The first step to identifying potential mediators of the intervention effect on alter CC screening was to identify variables that were associated with the intervention as well as alter CC screening. Starting with alter participant measures, Table
Linear regression models of intervention effects on index cervical cance... | PMC10173559 |
Moderators of the intervention effect on alter CC screening | precancerous lesions | REGRESSION, PRECANCEROUS LESIONS | In regression models examining moderation, receipt of thermal therapy for precancerous lesions by index participants was the only significant moderator of the intervention effect on alter CC screening [Adj. OR (95% CI) = 21.08 (1.78, 249.82)]. Figure
Moderating effects of index participant’s CC-related treatment statu... | PMC10173559 |
Discussion | pre-cancerous lesions | RECRUITMENT | Prior analysis of the study data revealed an effect of the GC-CCP intervention on increased CC screening uptake among previously unscreened social network members (alters) (15). In the analysis reported here, we sought to understand how the intervention achieved this effect, and for whom the intervention was most succe... | PMC10173559 |
Conclusion | Our study shows that the benefits of GC-CCP on alter uptake of CC screening are enhanced by the recipient of advocacy increasing her own advocacy for CC prevention and screening. The GC-CCP intervention had strong effects on nearly all components of the intervention, including index participants’ engagement in preventi... | PMC10173559 | ||
Acknowledgements | We acknowledge support from the staff of Buyinja Health Center IV and Banda Health Center III and the Study Coordinator (Grace Namisi) during the implementation of the GC-CC prevention advocacy intervention; and study participants for participating in this study. | PMC10173559 | ||
Authors’ contributions | G.W. conceived the study and led the analysis of data. J.K.B.M. supervised data collection, provided scientific oversight during the implementation of the intervention and drafted the manuscript. G.W., J.K.B.M. and R.K.W. supported the interpretation of study findings. N.E., M.J., S.N., K.B., L.E., and R.K.W. guided th... | PMC10173559 | ||
Funding | This research is funded by a grant from the US National Institutes of Health/Fogarty International Center (R21TW011728; PI: Wanyenze). | PMC10173559 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.